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The gap between the development of new 3Rs (replace, reduce, refine) technologies and their implementation into routine 
use has been called the “Valley of Death”1. Reasons for reluctance in adoption of these approaches, particularly by industry, 
are often complex, and may be related to a lack of awareness of, or confidence in, 3Rs approaches. We report from the 
Valley of Death, on a long-term project developing the social amoeba Dictyostelium discoideum as an innovative 3Rs 
alternative to the use of animals for early identification of novel chemical entities (NCEs) with aversive and emetic 
properties, to provide guidance so others may learn from our experience. 
 The side-effects of nausea and vomiting are factors limiting drug development or may reduce patient compliance 
for established treatments (Holmes et al., 2009); identification of emetic effects of candidate drugs utilises in vivo animal 
studies. A bitter or pungent taste of a medication can also reduce patent compliance particularly in paediatrics (Mennella et 
al., 2013) and bitter tastants can be nauseagenic (Peyrot des Gachons et al., 2011). The taste profile of candidate drugs is 
assessed by the rodent Brief Aversion Taste Assay (BATA) (e.g. Soto et al., 2015). In these experiments, around 12 animals 
are housed individually with some confinement , and with water deprivation, where a specially designed apparatus allows 
the number of licks taken from bottles containing test substance to be measured (Clapham et al., 2012). Lick number 
provides an estimation of aversive or bitter taste (Soto et al., 2015). The BATA test falls within the European Union 
legislation 2010/63/EU (EU, 2010) regulating the use of animals in research (e.g. Soto et al., 2015) as it exceeds the 
threshold for a regulated procedure. Although this method provides the industry standard, it is time consuming and requires 
animal experimentation as does testing for emetic liability. 
 Microorganisms were proposed as an early non-animal methodology (NAM) in a tiered approach to identification 
of emetic liability and aversive properties of NCEs (Holmes et al., 2009). The social amoeba Dictyostelium discoideum (Fig. 
1) was considered particularly attractive due to its use at the time in pharmacogenetic studies (Waheed et al., 2014; Chang et 
al., 2012; Kelly et al., 2018) and its recognition by the US National Institute of Health as a biomedical model system, and its 
use as an innovative model in a range of biomedical-related studies (Muller-Taubenberger et al., 2013). 
 
 
Fig. 1: The social amoeba Dictyostelium discoideum  
(A) Dictyostelium is found in leaf litter of temperate forests, with a single cells life involving the consumption of microorganisms 
and division by binary fission. Cells are around 10 μm long, and have a structure typical of eukaryotes (with a nucleus, 
endoplasmic reticulum, and mitochondria) and are haploid. Cells can be grown in the laboratory in nutrient-rich media or in the 
presence of bacteria as a food source. (B) Following the initiation of starvation, Dictyostelium cells progress through a series of 
stages leading to differentiation and multicellularity leading to the formation of a mature fruiting body, around 1mm tall, 
consisting of a spore head held aloft by a stalk. Spores within this structure are dormant, and resistant to dehydration, and upon 
release germinate to form single-celled amoeba. (C) This development process can be easily reproduced in laboratory 
conditions, and can be employed as a useful model for development and pharmacogenetic studies. 
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 In a series of papers, we reported the utility of Dictyostelium as a model for bitter and emetic substance screening. 
These studies established the utility of Dictyostelium to detect emetic agents and bitter tastants (Robery et al., 2011), 
including proposing novel molecular targets (Robery et al., 2013). They demonstrated that the model responds (cell 
movement and shape change) in a concentration-dependent manner to bitter tastants occupying a diverse chemical space, and 
showed a correlation of response data from eleven bitter tastants between Dictyostelium and the rat BATA assay which itself 
correlated with human taste panel data (Cocorocchio et al., 2015; Otto et al., 2016). Overall, these results support the use of 
Dictyostelium to estimate the probability that an NCE will have a bitter, aversive taste and hence its continued consideration 
as a potential 3Rs model in the drug discovery and development pipeline. Comparisons between the human taste panel, 
rodent BATA and Dictyostelium for the detection of potentially aversive (particularly bitter tasting) substances shows some 
of the key features and advantages of each system (Tab. 1). It is unlikely that one system will provide comprehensive data 
regarding a NAM, but selective combinations of multiple systems, including Dictyostelium, may provide a fast, cheap, and 
animal reduction approach. 
 
Tab. 1: Comparison between bitter tastant model systems 
Parameter 
 Human taste panel 
 





Yes Yes No 
Prior information on 
toxicity in vivo needed 
Yes Yes No 
Throughput capacity Relatively low Relatively low Relatively high 
Training required for 
subjects 
Yes Yes No 
Read out Perceived sensation & 
intensity  




collection and analysis 
possible 
Yes Yes Yes 
Detects concentration 
related effects 
Yes Yes Yes 
ED50 measurement Yes Yes Yes 
Time taken per 
compound to identify 
ED50 
Hours Days Hours 
Face validity Excellent Yes, but readout is the 
response to the taste 
rather than the sensation 
Limited 
Construct validity Yes Yes Yes 
Predictive validity Total Yes, based on relatively 
limited data 









Yes, but complex Yes, relatively 
straightforward 
 
 Despite the progress made over the last 10 years, much of it in collaboration with the potential end-user (i.e., 
industry), we have been unable to obtain further support to finally validate (or not) the Dictyostelium assay as a 
reduction/replacement technology for the BATA assay and exit the Valley of Death. The basis for this lack of support is 
likely to be multifactorial. Firstly, a single celled organism, without a mouth, gut or nervous system and lacking a range of 
proteins that may provide a mechanistic target for aversive effects clearly has limited face validity. Secondly, in this area 
industry seems fundamentally conservative, with a strong focus on maintaining consistent testing using established models. 
Finally, funding environments remain highly selective, with grant applications often relying upon guidance from experts 
working in currently established technologies without a drive to supplant these technologies with new approaches, and the 
smallest criticism can lead to the rejection of a funding application. In an industry setting, significant financial investment in 
novel technologies without a strategic decision to move into that technology is likely to block the development of new 
initiatives. Industry commitment to novel 3Rs technologies is sometimes difficult to identify. It is particularly interesting to 
note that one shortcoming of approaches for the development of alternative methods is “little input from end users”, and that 
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methods were produced that “did not adequately meet the testing requirements of end users”2. In our study, although we had 
input from a major industry partner at an early stage in the project to address these points, this did not ensure continued 
research support to fully assess the potential for industry adoption. 
 We believe that the barriers we have encountered are not unique and hence the lessons we have learned may have 
wider applicability; we make some recommendations for researchers looking to develop other NAMs. 
 1. Develop a relationship with industry partners. Key to implementing a new technology is to address all 
concerns of the end user, in this case our industrial partner. Thus, listening to their concerns, and addressing these issues is 
essential for them to ultimately engage with the technology. Relationships with industry can also give access to unpublished 
animal or human data enabling comparison with NAM data2 to facilitate validation. One difficulty with engaging large 
multinational partners is that it may be hard to find the right person to contact regarding 3Rs-orientated research, and 
ensuring that applications for funding reach both the 3Rs coordinator and the decision maker in the section where the 
technology will be relevant. In our case, trying to develop a novel technology to improve identification of a potential side 
effect was not a standard type of novel drug-target or mechanism-related approach regarding a particular therapeutic area. 
Furthermore, we had developed good working relationships with various industry colleagues, who understood and supported 
the new technology, but perhaps we should also have focused on developing relationships with those who decide on future 
research initiatives and subsequent investment. 
 2. Publish, publish, and publish. Validation of new technologies is considerably strengthened through the 
peer review process in publishing papers. Publications provide clear evidence of innovation or discovery that has been 
reviewed independently, increasing trust in the technology. This approach also enhances outreach and supports further 
funding applications. The journals to publish in may also be worth considering – where impact factor may not be as 
important as access to the target audience, and should this audience be the relevant industry-focused group, or those with 
specific interest in 3Rs-technology or a broad readership from all areas of science and society?  
 3. Network. Develop impact through targeted industry and academic networks. Presenting talks at industry, 
academic or government meetings is likely to both improve the potential for engaging industry partners and will additionally 
provide feedback on concerns that still need to be addressed. We gave at least 12 presentations on our Dictyostelium research 
model including several to predominantly industrial audiences, with subsequent discussions related to project and funding. 
 4. Don’t give up but recognise the limitations. With the highly competitive state of funding, all potential 
avenues of support must be investigated to maximise chances of continued investment, so keep looking for alternative 
mechanisms of support. However, projects such as this, where funding is required at the final step to validate a method for 
reduction/ replacement, are particularly problematic as the final data set (a graph of ID50 values for a range of substances in 
Dictyostelium vs. rodent, and human data) may look like the pilot data just with more data points and a better correlation 
statistic. In addition, the number of animals that would be replaced if Dictyostelium exactly matched the predictability of the 
BATA assay would be relatively small, partially because of repeated use of individuals. We suspect that a few thousand 
animals are used globally in the BATA assay but the number used by industry is impossible to know. In competition with 
projects developing methods aimed at reducing/replacing a large number of animals in procedures with severity classified as 
moderate or even severe (particularly involving pain) it seems inevitable that a project aiming to reduce/replace fewer 
animals in a mild procedure will have a lower priority. Finally, our project focuses on detecting a potential drug side effect 
rather than investigating disease or drug mechanisms and this may also reduce the priority in competition with other projects. 
 Thus, following 10 years of research into developing a 3Rs model for screening NCE for emetic and aversive 
effects, we have arrived in the Valley of Death from which few 3Rs projects seem to emerge. Through highlighting key 
points in advancing the development of new 3Rs technologies that we have recognised through this time, we hope to help 
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